ADVIKLA.BO · BSE
ADVIK LABORATORIES LTD.
₹2.18
+4.81% (+₹0.1)
Prev. close
₹2.08
Volume
100
As of
16 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range — no analyst has covered this yet.
Explore by date range →Analyst opinions
Fundamentals
About ADVIK LABORATORIES LTD.
MPS Pharmaa Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. The company offers generic products, including antibacterials, antiallergics, antifungals, anthelminthics, antihypertensives, antimalarials, antituberculosis, corticosteroids, erectile dysfunction, gastrointestinal agents, sedatives, and others, as well as analgesic, antipyretic, and anti-inflammatory products. It also provides ethical products, such as Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin, and Chewfe-C. In addition, the company exports its products to East Asia, Southeast Asia, the Middle East, South America, and Africa. The company was formerly known as Advik Laboratories Limited and changed its name to MPS Pharmaa Limited in December 2022. MPS Pharmaa Limited was incorporated in 1994 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Peeyush Kumar Aggarwal
Headquarters
New Delhi
Employees
18
Website
mpspharmaa.comExchange
View on BSE ↗Key stats
Market cap
₹3.98 Cr
Dividend yield
0.00%
EPS (TTM)
₹-0.55
Beta (1Y · daily vs NIFTY 50)
-0.00
Beta (5Y · monthly vs NIFTY 50)
0.12
Shares float
61.75 L
EPS · quarter ended Jun 2026
₹-0.12
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
Left off as not meaningful (growth from a very small base, beyond ±400%): Sales FY21 (+1200%).
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss — as filed
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹2.33 L | ₹9.37 L | ₹4.77 L | ₹3.56 L | |
Cost of materials consumed/expired | ₹4.50 L | — | — | — |
Employee benefits expense | ₹48.74 L | ₹52.77 L | ₹52.47 L | ₹53.31 L |
Finance costs | ₹5,368 | ₹12,521 | ₹4,983 | ₹7,810 |
Depreciation and amortization expense | ₹14.58 L | ₹14.67 L | ₹14.68 L | ₹14.68 L |
Other expenses | ₹41.55 L | ₹27.13 L | ₹23.96 L | ₹41.28 L |
Total expenses (IV) | ₹1.09 Cr | ₹94.70 L | ₹91.16 L | ₹1.09 Cr |
Profit/(loss) before exceptional items and tax (III-IV) | ₹-1.07 Cr | ₹-85.33 L | ₹-86.39 L | ₹-1.06 Cr |
Profit/(loss) before tax (V-VI) | ₹-1.07 Cr | ₹-85.33 L | ₹-86.39 L | ₹-1.06 Cr |
(2) Deferred tax expenses/(Income) | ₹-2.06 L | ₹-2.23 L | ₹2,783 | ₹-3.79 L |
(3) Earlier year MAT Credit Adjustment | — | — | ₹3.38 L | — |
Profit (Loss) after Tax | ₹-1.05 Cr | ₹-83.10 L | ₹-89.79 L | ₹-1.02 Cr |
| ₹-1.04 Cr | — | — | — | |
| — | ₹85,969† | ₹98,396 | ₹78,269 | |
Total Comprehensive Income for the period | ₹1.52 L | ₹-82.24 L | ₹-88.81 L | ₹-1.01 Cr |
(1) Basic | -0.55 | -0.43 | -0.47 | -0.53 |
(2) Diluted | -0.55 | -0.43 | -0.47 | -0.53 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.
‡ The company printed this figure on a line with no label (a bare subtotal under a block). Where the lines above add up to it, it is named after them; otherwise it is shown as “Unlabelled line”. The figure is the company’s own.
All years: standalone statements.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹10.19 Cr | ₹9.94 Cr | ₹9.33 Cr | ₹8.48 Cr | |
| — | — | ₹6.76 Cr | ₹7.27 Cr | ₹7.46 Cr | ₹7.52 Cr | |
Stockholders' equity | — | — | ₹2.79 Cr | ₹1.97 Cr | ₹1.08 Cr | ₹6.85 L |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY23 |
|---|---|
| ₹-86.55 L | |
| ₹-9.73 L | |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: standalone statements.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| ADVIK LABORATORIES LTD. | ₹3.98 Cr | ₹2.08 | — | 58.01 | -1488.5% | 109.80 | — | +9.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.